The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MOF Urges Full Annual Price Cuts, “At Least Stepwise Reductions” in Adjustment Rate
The Ministry of Finance (MOF) on April 13 renewed its calls for the full-scale implementation of annual drug price cuts, while pressing for “at least stepwise reductions” in the current 2% adjustment rate used in the revision formula to soften…
To read the full story
Related Article
- MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
November 21, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
- MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
- Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
- MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
- MOF Calls for Stepwise Cuts in 2% Adjustment Rate, Timeline towards Abolishment
November 9, 2021
- Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…